 SAN DIEGO NEW YORK--BUSINESS WIRE--- IMVT ClassAction--Shareholder rights law firm Robbins LLP announces that a purchaser of Immunovant, Inc. NASDAQ: IMVT filed a class action complaint against the Company and its officers and directors for alleged violations of the Securities Exchange Act of 1934 between October 2, 2019 and February 1, 2021. Immunovant is a clinical-stage biopharmaceutical company. The Company is developing IMVT-1401, which is in Phase IIa clinical trials for the treatment of Graves ophtha 